News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

China Drugmaker Access May Require Profit Cut, Chen Says, National Foundation for Cancer Research Reveals


4/9/2013 7:25:39 AM

Western drugmakers may have to give hefty subsidies and forgo some profit on expensive cancer drugs if they want access to China’s “huge market,” the country’s former health minister said. With the cost of some oncology drugs topping $100,000 a year, Chinese officials may increasingly push for deals like one reached last year with Novartis AG (NOVN), in which the company agreed to donate three doses of its leukemia drug Gleevec for every one sold to the government, the former minister, Chen Zhu, said during an interview in Washington, D.C.

Read at Bloomberg


comments powered by Disqus
Bloomberg
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES